Shanghai Peptidstar Therapeutics

Peptidstar Therapeutics is a clinical-stage biotechnology company headquartered in Shanghai, China, focused on developing transformative treatments for chronic viral infections and metabolic disorders. The company utilizes its proprietary PeptidStar platform to engineer next-generation peptide therapeutics and siRNA-based medicines. Its primary focus is achieving a functional cure for chronic Hepatitis B (CHB) through a diversified pipeline, including the GalNAc-siRNA candidate HT-101 and the TLR8 agonist HT-102. By integrating advanced drug delivery technologies with deep expertise in peptide chemistry, Peptidstar aims to provide highly effective and convenient treatment options for patients worldwide.